{"id":"mirtazapine-tablets","safety":{"commonSideEffects":[{"rate":"54","effect":"Sedation"},{"rate":"12-17","effect":"Weight gain"},{"rate":"17","effect":"Increased appetite"},{"rate":"9","effect":"Dizziness"},{"rate":"13","effect":"Dry mouth"},{"rate":"13","effect":"Constipation"},{"rate":"0.02","effect":"Agranulocytosis (rare)"}]},"_chembl":{"chemblId":"CHEMBL654","moleculeType":"Small molecule","molecularWeight":"265.36"},"_fixedAt":"2026-03-30T17:50:45.495488","_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"As a tetracyclic antidepressant, mirtazapine antagonizes presynaptic alpha-2 adrenergic autoreceptors and heteroreceptors, which disinhibits the release of norepinephrine and serotonin. It also blocks postsynaptic 5-HT2 and 5-HT3 receptors, further enhancing serotonergic signaling. This dual mechanism increases monoamine availability in key brain regions involved in mood regulation.","oneSentence":"Mirtazapine blocks alpha-2 adrenergic receptors and serotonin 5-HT2 and 5-HT3 receptors, increasing noradrenergic and serotonergic neurotransmission in the central nervous system.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:55:20.248Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Major depressive disorder"},{"name":"Off-label use for anxiety disorders, insomnia, and appetite stimulation"}]},"_fixedFields":["pubmed(4)"],"trialDetails":[{"nctId":"NCT00488072","phase":"PHASE2","title":"Effects of Mirtazapine on Appetite in Advanced Cancer Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2007-01-08","conditions":"Advanced Cancer, Anorexia, Weight Loss","enrollment":98},{"nctId":"NCT06499090","phase":"EARLY_PHASE1","title":"Mirtazapine for Acute and Chronic Post Mastectomy Pain","status":"COMPLETED","sponsor":"Assiut University","startDate":"2024-03-01","conditions":"Breast Cancer","enrollment":62},{"nctId":"NCT05452174","phase":"PHASE1, PHASE2","title":"Endeavor to Stop Nausea/Vomiting Associated With Pregnancy (E-SNAP)","status":"WITHDRAWN","sponsor":"Northwestern University","startDate":"2022-06-13","conditions":"Pregnancy, Severe Nausea and Vomiting, Hyperemesis Gravidarum","enrollment":""},{"nctId":"NCT04547842","phase":"EARLY_PHASE1","title":"Mirtazapine Versus Dexamethasone in Preventing Postoperative Nausea and Vomiting","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2020-09-01","conditions":"Post Operative Nausea and Vomiting","enrollment":90},{"nctId":"NCT00835575","phase":"PHASE1","title":"15 mg Mirtazapine Orally Disintegrating Tablets, Fasting","status":"COMPLETED","sponsor":"Teva Pharmaceuticals USA","startDate":"2003-07","conditions":"Healthy","enrollment":32},{"nctId":"NCT00834197","phase":"PHASE1","title":"15 mg Mirtazapine Orally Disintegrating Tablets, Non-Fasting","status":"COMPLETED","sponsor":"Teva Pharmaceuticals USA","startDate":"2003-07","conditions":"Healthy","enrollment":32},{"nctId":"NCT05247697","phase":"PHASE1","title":"Mirtazapine for Chronic Insomnia in Older Adults","status":"COMPLETED","sponsor":"Centre hospitalier de l'Université de Montréal (CHUM)","startDate":"2022-10-01","conditions":"Chronic Insomnia","enrollment":60},{"nctId":"NCT05978219","phase":"PHASE4","title":"Efficacy of Mirtazapine in Major Depressive Disorder With Insomnia","status":"COMPLETED","sponsor":"National Institute of Mental Health, Dhaka","startDate":"2023-05-25","conditions":"Major Depressive Disorder With Insomnia","enrollment":135},{"nctId":"NCT05108688","phase":"PHASE4","title":"Mirtazapine vs Sumatriptan in the Treatment of Postdural Puncture Headache","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2021-11-15","conditions":"Headache","enrollment":210},{"nctId":"NCT06213948","phase":"PHASE1","title":"Elucidating Mechanisms That Underlie the Symptomatology of Functional Dyspepsia Using Novel Techniques and Its Therapeutic Validation Using Neuromodulators","status":"UNKNOWN","sponsor":"Universiti Sains Malaysia","startDate":"2021-08-01","conditions":"Functional Disorder of Stomach, Healthy","enrollment":54},{"nctId":"NCT03283488","phase":"PHASE2","title":"Comparison Between Mirtazapine and Megestrol for the Control of Anorexia-cachexia in Cancer Patients in Palliative Care.","status":"COMPLETED","sponsor":"University of Sao Paulo","startDate":"2019-03-26","conditions":"Cachexia; Cancer, Anorexia","enrollment":52},{"nctId":"NCT04763135","phase":"PHASE3","title":"Mirtazapine in Cancer-related Poly-symptomatology","status":"TERMINATED","sponsor":"Hospices Civils de Lyon","startDate":"2021-12-15","conditions":"Cancer, Neoplasms, Neoplasm Metastasis","enrollment":1},{"nctId":"NCT04748523","phase":"NA","title":"Effect of Mirtazapine Versus Placebo in Patients With Non-small Cell Lung Cancer and Anorexia","status":"COMPLETED","sponsor":"Instituto Nacional de Cancerologia de Mexico","startDate":"2018-08-29","conditions":"Anorexia, Non-small Cell Lung Cancer","enrollment":86},{"nctId":"NCT05737511","phase":"PHASE4","title":"Efficacy of Hydroxyzine for Patients With Panic Disorder","status":"NOT_YET_RECRUITING","sponsor":"Sultan Qaboos University","startDate":"2023-12-30","conditions":"Panic Disorder","enrollment":80},{"nctId":"NCT03785691","phase":"PHASE2","title":"Validating the Effect og Ondansetron and Mirtazapine in Treating Hyperemesis Gravidarum","status":"TERMINATED","sponsor":"Nordsjaellands Hospital","startDate":"2019-03-01","conditions":"Hyperemesis Gravidarum, Nausea Gravidarum, Vomiting of Pregnancy","enrollment":58},{"nctId":"NCT05380479","phase":"PHASE2","title":"Mirtazapine Versus Megestrol Acetate in Treatment of Anorexia-cachexia in Advanced Cancer Patients.","status":"UNKNOWN","sponsor":"Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh","startDate":"2022-06-01","conditions":"Anorexia","enrollment":80},{"nctId":"NCT02336750","phase":"PHASE3","title":"Adding Mirtazapine to Dexamethasone and Aprepitant for Delayed Emesis","status":"COMPLETED","sponsor":"Fudan University","startDate":"2014-12","conditions":"Breast Cancer","enrollment":212},{"nctId":"NCT04908605","phase":"PHASE4","title":"Emergence Agitation After Nasal Surgery: a Randomized Controlled Comparison Between Melatonin and Mirtazapine","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2021-06-15","conditions":"Agitation","enrollment":165},{"nctId":"NCT03921151","phase":"PHASE1, PHASE2","title":"5HT2CR Balance in Brain Connectivity in Cocaine Dependence","status":"COMPLETED","sponsor":"Virginia Commonwealth University","startDate":"2014-05-13","conditions":"Cocaine Dependence","enrollment":90},{"nctId":"NCT00750919","phase":"PHASE3","title":"Twenty-six Week Extension Trial of Org 50081 (Esmirtazapine) in Outpatients With Chronic Primary Insomnia (176003/P05721/MK-8265-007)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-10-07","conditions":"Sleep Initiation and Maintenance Disorders, Mental Disorders, Dyssomnias","enrollment":184},{"nctId":"NCT00561574","phase":"PHASE3","title":"A Long-Term Safety Study of Org 50081 (Esmirtazapine) in Elderly Outpatients With Chronic Primary Insomnia (176005/P05697/MK-8265-001)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-01-09","conditions":"Sleep Initiation and Maintenance Disorder; Elderly, Mental Disorder, Dyssomnias","enrollment":259},{"nctId":"NCT03675555","phase":"PHASE4","title":"Prophylactic Mirtazapine or Dexamethasone for Post-spinal Anesthesia Shivering","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2018-03-01","conditions":"Shivering","enrollment":300},{"nctId":"NCT03254173","phase":"PHASE2, PHASE3","title":"Mirtazapine for Treatment of Cancer Associated Anorexia-cachexia","status":"COMPLETED","sponsor":"Catherine Naseef Hunter","startDate":"2018-03-26","conditions":"Advanced Cancer, Cancer Associated Anorexia - Cachexia","enrollment":120},{"nctId":"NCT04013386","phase":"PHASE4","title":"Effects of Aprepitant/Dexamethasone Versus Mertazepine /Dexamethasone on Postoperative Nausea and Vomiting","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2019-07-15","conditions":"Nausea and Vomiting, Postoperative","enrollment":90},{"nctId":"NCT00535288","phase":"PHASE3","title":"Dose-Finding Safety and Efficacy Trial of Org 50081 (Esmirtazapine) in the Treatment of Vasomotor Symptoms (177001/P06472/MK-8265-013)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2004-09-15","conditions":"Postmenopausal Symptoms, Menopause, Vasomotor Symptoms","enrollment":946},{"nctId":"NCT00560833","phase":"PHASE3","title":"Dose-Finding Safety and Efficacy Trial of Org50081 (Esmirtazapine) in the Treatment of Vasomotor Symptoms (46101/P06459/MK-8265-012)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2004-10-15","conditions":"Menopause, Vasomotor Symptoms","enrollment":943},{"nctId":"NCT00482612","phase":"PHASE3","title":"Study of the Safety and Effectiveness of Esmirtazapine in Participants With Chronic Primary Insomnia (P05706)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2006-12-07","conditions":"Insomnia","enrollment":526},{"nctId":"NCT00561821","phase":"PHASE3","title":"Efficacy and Safety Study of Org 50081 (Esmirtazapine) in Elderly Participants (P05709)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-11-20","conditions":"Insomnia, Sleep Initiation and Maintenance Disorders, Mental Disorders","enrollment":538},{"nctId":"NCT00610675","phase":"PHASE3","title":"Fifty Two Week Extension Trial of Org 50081 (Esmirtazapine) in the Treatment of Insomnia (P05708)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2006-12-07","conditions":"Insomnia","enrollment":346},{"nctId":"NCT00631657","phase":"PHASE3","title":"A 6-Month Efficacy and Safety Study of Org 50081 in Adult Patients With Chronic Primary Insomnia (21106/P05701/MK-8265-002)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-03-04","conditions":"Sleep Initiation and Maintenance Disorders, Mental Disorders, Dyssomnias","enrollment":460},{"nctId":"NCT00506389","phase":"PHASE3","title":"A Six Week, Double-Blind Randomized, Efficacy and Safety, Sleep Lab Trial With Esmirtazapine (Org 50081) (P05707)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-06-06","conditions":"Insomnia","enrollment":419},{"nctId":"NCT03679052","phase":"PHASE4","title":"Prophylactic Mirtazapine or Clonidine for Post-spinal Anesthesia Shivering","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2018-03-01","conditions":"Shivering","enrollment":300},{"nctId":"NCT02400346","phase":"PHASE3","title":"Evaluation of the Safety of Adjunct Brexpiprazole in Elderly Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Treatment","status":"COMPLETED","sponsor":"H. Lundbeck A/S","startDate":"2015-03","conditions":"Major Depression Disorder","enrollment":132},{"nctId":"NCT01263080","phase":"PHASE4","title":"Evaluation of Mirtazapine and Folic Acid for Schizophrenia:","status":"COMPLETED","sponsor":"Capital Medical University","startDate":"2010-11","conditions":"Schizophrenia","enrollment":333},{"nctId":"NCT01178671","phase":"PHASE4","title":"Combined Mirtazapine and SSRI Treatment of PTSD: A Placebo-Controlled Trial","status":"COMPLETED","sponsor":"Research Foundation for Mental Hygiene, Inc.","startDate":"2010-07","conditions":"Posttraumatic Stress Disorder","enrollment":38},{"nctId":"NCT00302107","phase":"PHASE4","title":"A Placebo-Controlled Study of Mirtazapine for PTSD","status":"COMPLETED","sponsor":"US Department of Veterans Affairs","startDate":"2006-04","conditions":"Anxiety, PTSD","enrollment":78},{"nctId":"NCT01949571","phase":"PHASE2","title":"Clinical Studies on the Therapeutic Effects of Mirtazapine on Drug-craving in Cocaine Addicts.","status":"COMPLETED","sponsor":"Instituto Nacional de Psiquiatría Dr. Ramón de la Fuente","startDate":"2007-01","conditions":"Drug-withdrawal., Drug Abuse, Drug-induced Depressive State","enrollment":64},{"nctId":"NCT00919295","phase":"PHASE2","title":"Study of Indoleamine 2,3-dioxygenase Activity, Serum Levels of Cytokines, BDNF, BH4 and Mirtazapine Efficacy in Fibromyalgia Syndrome","status":"COMPLETED","sponsor":"Mahidol University","startDate":"2008-12","conditions":"Fibromyalgia Syndrome","enrollment":80},{"nctId":"NCT01119924","phase":"PHASE4","title":"A Clinical Study for Assessment of the Efficacy and Safety of Mirtazapine (Smilon) in Depression Patients With Pain","status":"COMPLETED","sponsor":"Nang Kuang Pharmaceutical Co., Ltd.","startDate":"2009-12","conditions":"Depression, Pain","enrollment":30},{"nctId":"NCT00865696","phase":"PHASE1","title":"A Relative Bioavailability Study of Mirtazapine 15 mg Tablets Under Fasting Conditions","status":"COMPLETED","sponsor":"Actavis Inc.","startDate":"2001-09","conditions":"Healthy","enrollment":32},{"nctId":"NCT00865384","phase":"PHASE1","title":"A Relative Bioavailability Study of Mirtazapine 15 mg Tablets Under Non-fasting Conditions","status":"COMPLETED","sponsor":"Actavis Inc.","startDate":"2001-09","conditions":"Healthy","enrollment":24},{"nctId":"NCT00960830","phase":"NA","title":"Mirtazapine Reduces ICD Shocks in ICD Patients With Depression and Anxiety","status":"COMPLETED","sponsor":"Universidad Nacional de Rosario","startDate":"2007-04","conditions":"Depression, Anxiety","enrollment":40},{"nctId":"NCT00874003","phase":"PHASE2","title":"The Effects of Mirtazapine Versus Placebo on Alcohol Consumption in Male Alcohol High Consumers","status":"COMPLETED","sponsor":"Sahlgrenska University Hospital","startDate":"2004-04","conditions":"Alcohol Dependence","enrollment":59}],"_emaApprovals":[],"_faersSignals":[{"count":31,"reaction":"DRUG INEFFECTIVE"},{"count":21,"reaction":"INSOMNIA"},{"count":19,"reaction":"SOMNOLENCE"},{"count":18,"reaction":"COMPLETED SUICIDE"},{"count":16,"reaction":"DIZZINESS"},{"count":15,"reaction":"HEADACHE"},{"count":15,"reaction":"OFF LABEL USE"},{"count":14,"reaction":"DIARRHOEA"},{"count":13,"reaction":"PRODUCT SUBSTITUTION ISSUE"},{"count":12,"reaction":"ANXIETY"}],"_approvalHistory":[],"publicationCount":4,"recentPublications":[{"date":"2022 Feb","pmid":"34558297","title":"Financial Burden of Drugs Prescribed for Cancer-Associated Symptoms.","journal":"JCO oncology practice"},{"date":"2020 Nov-Dec","pmid":"33666194","title":"Bradyarrhythmia due to mirtazapine overdose: A case of serious adverse event in a suicidal patient.","journal":"Indian journal of pharmacology"},{"date":"2017 Jan 17","pmid":"28096225","title":"Not so patchy story of attempted suicide…leading to 24 hours of deep sleep and survival!","journal":"BMJ case reports"},{"date":"2009","pmid":"24916729","title":"Treating depression with different galenical drug formulations: Does it make a difference? The comparison of mirtazapine fast dissolving formulation (FDT) with conventional mirtazapine tablets (CT).","journal":"International journal of psychiatry in clinical practice"}],"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Mirtazapine Tablets","genericName":"Mirtazapine Tablets","companyName":"National Institute of Mental Health, Dhaka","companyId":"national-institute-of-mental-health-dhaka","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Mirtazapine tablets are a small molecule serotonin 2a (5-HT2a) receptor antagonist used to treat various conditions, including major depression disorder and drug withdrawal. They are classified as an antagonist and have been studied in clinical trials for other conditions such as headache and non-small cell lung cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}